Methods for overcoming WNT/beta-catenin anti-cancer resistance in leukemia stem cells
US12186332B2 · kind B2 · utility
0Cited by
1References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 26, 2020 |
| Grant date | Jan 7, 2025 |
| Priority date | — |
| Expiry date | Aug 21, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides, inter alia, methods for treating cancers including leukemia using low doses of an anthracycline such as doxorubicin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.